์ฐ๊ตฌ์ฉ
์ ํ ๋ฒํธS7062
| ๊ด๋ จ ํ๊ฒ | HDAC JAK BET PKC PARP HIF PRMT EZH2 AMPK Histone Acetyltransferase |
|---|---|
| ๊ธฐํ Histone Methyltransferase ์ต์ ์ | 3-Deazaneplanocin A (DZNep) Hydrochloride BIX-01294 Trihydrochloride EPZ015666 (GSK3235025) EPZ004777 UNC1999 MM-102 (HMTase Inhibitor IX) Chaetocin SGC 0946 EPZ005687 UNC0638 |
| ์ธํฌ์ฃผ | ๋ถ์ ์ ํ | ๋๋ | ๋ฐฐ์ ์๊ฐ | ์ ํ | ํ์ฑ ์ค๋ช | PMID |
|---|---|---|---|---|---|---|
| MV4-11 | Function assay | 4 days | Inhibition of DOT1L in human MV4-11 cells expressing MLL-AF4 assessed as reduction of H3K79me2 level after 4 days by ELISA method | 25406853 | ||
| MOLM13 | Proliferation assay | Antiproliferative activity against human MOLM13 cells containing MLL-AF9, EC50=4 nM | 23879463 | |||
| MV4-11 | Proliferation assay | Antiproliferative activity against human MV4-11 cells containing MLL-AF4, EC50=4 nM | 23879463 | |||
| THP1 | Proliferation assay | Antiproliferative activity against human THP1 cells containing MLL-AF9, EC50=4 nM | 23879463 | |||
| HeLa | Function assay | 72 hrs | Inhibition of DOT1L in human HeLa cells assessed as reduction in H3K79me2 level after 72 hrs by ELISA, IC50 = 0.007 ฮผM. | 28337327 | ||
| MV4-11 | Antiproliferative assay | 6 hrs | Antiproliferative activity against human MV4-11 cells harboring MLL-AF4 treated for 6 hrs measured after 8 days by Celltiter-Glo reagent based assay, IC50 = 0.015 ฮผM. | 28337327 | ||
| MOLM13 | Function assay | 72 hrs | Inhibition of DOT1L in human MOLM13 cells assessed as suppression of HoxA9 gene after 72 hrs by luciferase reporter gene assay, IC50 = 0.052 ฮผM. | 28337327 | ||
| ํด๋ฆญํ์ฌ ๋ ๋ง์ ์ธํฌ์ฃผ ์คํ ๋ฐ์ดํฐ ๋ณด๊ธฐ | ||||||
| ๋ถ์๋ | 562.71 | ํํ์ | C30H42N8O3 |
๋ณด๊ด (์๋ น์ผ๋ก๋ถํฐ) | |
|---|---|---|---|---|---|
| CAS ๋ฒํธ | 1380288-87-8 | SDF ๋ค์ด๋ก๋ | ์์ก ๋ณด๊ด |
|
|
| ๋์์ด | N/A | Smiles | CC(C)N(CC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)O)C4CC(C4)CCC5=NC6=C(N5)C=C(C=C6)C(C)(C)C | ||
|
In vitro |
DMSO
: 100 mg/mL
(177.71 mM)
Ethanol : 25 mg/mL Water : Insoluble |
|
In vivo |
|||||
1๋จ๊ณ: ์๋ ์ ๋ณด ์ ๋ ฅ (๊ถ์ฅ: ์คํ ์ค ์์ค์ ๊ณ ๋ คํ์ฌ ์ถ๊ฐ ๋๋ฌผ ํฌํจ)
2๋จ๊ณ: ์์ฒด ๋ด ์ ํ ์ ๋ ฅ (์ด๊ฒ์ ๊ณ์ฐ๊ธฐ์ผ ๋ฟ ์ ํ์ด ์๋๋๋ค. ์ฉํด๋ ์น์ ์ ์์ฒด ๋ด ์ ํ์ด ์๋ ๊ฒฝ์ฐ ๋จผ์ ๋น์ฌ์ ๋ฌธ์ํ์ญ์์ค.)
๊ณ์ฐ ๊ฒฐ๊ณผ:
์์ ๋๋: mg/ml;
DMSO ์์ก ์ค๋น ๋ฐฉ๋ฒ: mg ์ฝ๋ฌผ ์ฌ์ ์ฉํด ฮผL DMSO ( ์์ก ๋๋ mg/mL, ๋๋๊ฐ ํด๋น ์ฝ๋ฌผ ๋ฐฐ์น์ DMSO ์ฉํด๋๋ฅผ ์ด๊ณผํ๋ ๊ฒฝ์ฐ ๋จผ์ ๋น์ฌ์ ๋ฌธ์ํ์ญ์์ค. )
์์ฒด ๋ด ์ ํ ์ค๋น ๋ฐฉ๋ฒ: ์ทจํ๋ค ฮผL DMSO ์์ก, ๋ค์ ์ถ๊ฐฮผL PEG300, ํผํฉํ๊ณ ํฌ๋ช ํ๊ฒ ํ ๋ค์ ์ถ๊ฐฮผL Tween 80, ํผํฉํ๊ณ ํฌ๋ช ํ๊ฒ ํ ๋ค์ ์ถ๊ฐ ฮผL ddH2O, ํผํฉํ๊ณ ํฌ๋ช ํ๊ฒ ํฉ๋๋ค.
์์ฒด ๋ด ์ ํ ์ค๋น ๋ฐฉ๋ฒ: ์ทจํ๋ค ฮผL DMSO ์์ก, ๋ค์ ์ถ๊ฐ ฮผL ์ฅ์์ ๊ธฐ๋ฆ, ํผํฉํ๊ณ ํฌ๋ช ํ๊ฒ ํฉ๋๋ค.
์ฐธ๊ณ : 1. ๋ค์ ์ฉ๋งค๋ฅผ ์ถ๊ฐํ๊ธฐ ์ ์ ์ก์ฒด๊ฐ ํฌ๋ช
ํ์ง ํ์ธํ์ญ์์ค.
2. ์ฉ๋งค๋ฅผ ์์๋๋ก ์ถ๊ฐํด์ผ ํฉ๋๋ค. ๋ค์ ์ฉ๋งค๋ฅผ ์ถ๊ฐํ๊ธฐ ์ ์ ์ด์ ์ถ๊ฐ์์ ์ป์ ์ฉ์ก์ด ํฌ๋ช
ํ ์ฉ์ก์ธ์ง ํ์ธํด์ผ ํฉ๋๋ค. ์๋, ์ด์ํ ๋๋ ๋จ๊ฑฐ์ด ๋ฌผ ์คํ๊ณผ ๊ฐ์ ๋ฌผ๋ฆฌ์ ๋ฐฉ๋ฒ์ ์ฌ์ฉํ์ฌ ์ฉํด๋ฅผ ๋์ธ ์ ์์ต๋๋ค.
| Targets/IC50/Ki |
DOT1L
(Cell-free assay) 80 pM(Ki)
|
|---|---|
| ์ํ๊ด ๋ด(In vitro) |
EPZ-5676 reduces H3K79 dimethylation with a cellular IC50 of 2.6 nM in MV4-11 cells. EPZ-5676 treatment results in concentration- and time-dependent reduction of H3K79 methylation without effect on the methylation status of other histone sites, which leads to inhibition of key MLL target genes and selective, apoptotic cell killing in MLL-rearranged leukemia cells. EPZ-5676 inhibits proliferation of MLL-AF4 rearranged cell line MV4-11 with an IC50 of 9 nM. |
| ์์ฒด ๋ด(In vivo) |
EPZ-5676 continuously intravenous infusion for 21 days to xenograft model of MLL-rearranged leukemia, leads to dose-dependent anti-tumor activity. At the highest dose of 70.5 mg/kg/day, complete tumor regressions are achieved with no regrowth for up to 32 days after the cessation of treatment. No significant weight loss or obvious toxicity is observed in rats treated with EPZ-5676 during efficacy study. |
์ฐธ์กฐ |
|
| ๋ฐฉ๋ฒ | ๋ฐ์ด์ค๋ง์ปค | ์ด๋ฏธ์ง | PMID |
|---|---|---|---|
| Western blot | p-p65 / p65 / NFATc1 CDK6 / BCL11A / Bcl-2 / RUNX1 / MEF2C / H3K79me3 / H4 |
|
29348610 |
| Immunofluorescence | NFATc1 |
|
29348610 |
(๋ฐ์ดํฐ ์ถ์ฒ https://clinicaltrials.gov, ์ ๋ฐ์ดํธ ๋ ์ง 2024-05-22)
| NCT ๋ฒํธ | ๋ชจ์ง | ์กฐ๊ฑด | ์คํฐ์/ํ๋ ฅ์ | ์์์ผ | ๋จ๊ณ |
|---|---|---|---|---|---|
| NCT02141828 | Completed | Leukemia|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Acute Leukemias |
Epizyme Inc.|Celgene Corporation|Ipsen |
May 2014 | Phase 1 |
| NCT01684150 | Completed | Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome|Myeloproliferative Disorders |
Epizyme Inc.|Celgene|Ipsen |
September 2012 | Phase 1 |
์ง๋ฌธ 1:
Is the vehicle 30% PEG400/0.5% Tween80/5% propylene glycol recommended for in vivo use?
๋ต๋ณ:
S7062 in 30% PEG400/0.5% Tween80/5% propylene glycol at 30 mg/ml is a suspension. For injection, 2% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml is suitable.